Term
|
Definition
hepatotoxicity
dizziness/OSH
increased CV events- MI (caution)
CYP3A4 Substrate
not 1st line
Tropism assay prior to tx!!! |
|
|
Term
|
Definition
bind to gp41
injection site reactions
inc. risk pneumonia
counseling points...
e$$pensive
not 1st line |
|
|
Term
|
Definition
lactic acidosis with hepatic steatosis
(non specific s/sx)
NOT inhibitors OR inducers of CYP 450
RENAL DOSE (except for one..) |
|
|
Term
|
Definition
BONE MARROW SUPPRESSION
myopathy
nail pigmentation
NAUSEA, headache
antag. with d4T
can be used intrapartum |
|
|
Term
|
Definition
pancreatitis
peripheral neuropathy
non-cirrhotic portal hypertension (?)
TDF incr. Cmax and AUC
WEIGHT based
usually ES. but if TDF usually with food |
|
|
Term
|
Definition
lipoatrophy
hyperlipidemia
DI with AZT
WEIGHT BASED
not really used. womp womp. |
|
|
Term
|
Definition
well tolerated
hbv activity
flare if abrupt d/c |
|
|
Term
|
Definition
well tolerated
hyperpigmentation of palms and soles
hpv activity
flare if abrupt d/c |
|
|
Term
|
Definition
possible inc. risk of MI
hypersensitivity rxn- HLA-B*5701
no renal adj.! yayyy |
|
|
Term
|
Definition
nucleoTIDE- phosphorylated 2x
pretty well tolerated (mostly GI)
nephrotoxicity- monitor sCr
DI with ddI, ATV
activity against HBV |
|
|
Term
|
Definition
Rash
Hepatotoxicity
impact CYP system!
lower genetic barrier to resistance- NEED REAL GOOD ADHERENCE |
|
|
Term
|
Definition
heptotox. and rash more problematic
not recommended for women
HPV and HCV co-infection
CYP inducer
dose titration at start |
|
|
Term
|
Definition
CNS effects
mixed cyp inhibitor/inducer
food inc. concentrations (mickey's D)- Take on ES
Teratogenicity
+ cannabinoid test |
|
|
Term
|
Definition
|
|
Term
|
Definition
may be effective a/g NVP or EFV resistant strains
GI (if any)
NEED FOOD.. (food inc. absorption)
CYP3A4-inducer
not 1st line
BID (WITH FOOD)
tablets dispersable in water |
|
|
Term
|
Definition
2nd. Gen.
avoid with high viral loads (>100,000)
taken with food, (high fat)
DI with acid reducing, dexamethasone |
|
|
Term
|
Definition
GI upset, HA, elevation in CPK (generally well-tolerated)
DI by UGT 131
BID
hepatic metabolism |
|
|
Term
|
Definition
resistance (BE MORE ADHERENT)
hepatic metabolism- no renal adjustment
lipodystrophy
changes in lipids
insulin resistance
elevated transaminases
GI upset
inc. bleeding in hemophiliacs
DRUG INTERACTIONS!!- all CYP3A4 Inhibitors
most must be taken with food |
|
|
Term
|
Definition
hyperbilirubinemia (cosmetic)
nephrolithiasis
OTc prolongation
skin rash
DI (see class ones)
acid reducing agents
tenofovir
standard doing- interaction based |
|
|
Term
|
Definition
skin rash (sulfa moiety)
boosting needed
dosing based on experience |
|
|
Term
|
Definition
perioral paresthesias, taste disturbances, more GI intolerability, lipid abnl
boooooostaaah
dosing different in for use alone and for us in combo
refig capsules |
|
|
Term
|
Definition
gi and lipid abnml (TG)
pancreatitis
booster included
soln with food and refig.
dosing based on experience |
|
|
Term
|
Definition
sulfa moiety (caution)
unboosted- no req.
boosted- with food
susp- with food
prodrug of amprenavir
dosing based on experience |
|
|
Term
|
Definition
| nephrolithiasis, hyperbilirubinemia, ES if unboosted |
|
|
Term
|
Definition
|
|
Term
|
Definition
| Hepatitis, rash, ICH, sulfa moiety, ref. capsules, soln RT |
|
|
